Clinical Trials Sponsored by Royal (Wuxi) Biological Co., LTD

Total 415 results

Jiangsu Province Centers for Disease Control and...
Royal (Wuxi) Biological Co., LTD

Completed

Immunogenicity and Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Infants and Children

Group A, C Polysaccharide Meningitis | Type b Haemophilus Influenza

China
Jiangsu Province Centers for Disease Control and...
Royal (Wuxi) Biological Co., LTD

Completed

Phase 3 Study of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine

Influenza | Meningitis

China
Jiangsu Province Centers for Disease Control and...
Royal (Wuxi) Biological Co., LTD

Completed

Safety of A Group A, C Polysaccharide Meningococcal and Type b Haemophilus Influenzal Conjugate Vaccine in Children

Healthy

China
D3 Bio (Wuxi) Co., Ltd

Recruiting

Study of D3S-002 as Monotherapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations

Advanced Solid Tumors With MAPK Pathway Mutations

Australia, China, United States
Cutia Therapeutics（Wuxi）Co.,Ltd

Not yet recruiting

Efficacy and Safety of Lidocaine and Tetracaine Cream for Facial Laser Aesthetics in Chinese Adults

Analgesia

China
D3 Bio (Wuxi) Co., Ltd

Recruiting

A Study of D3S 001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

KRAS P.G12C

Australia, Korea, Republic of, China, United States, Hong Kong
Cutia Therapeutics（Wuxi）Co.,Ltd

Recruiting

A Phase 1 Clinical Study of CU-20401 in Chinese Healthy Population

Healthy Subjects

China
Cutia Therapeutics（Wuxi）Co.,Ltd

Completed

a Clinical Study to Evaluate the Safety, Pharmacokinetic Profile and Efficacy of CU-20401

Safety

China
Cutia Therapeutics（Wuxi）Co.,Ltd

Recruiting

A Phase I Clinical Trial Evaluating the Safety, Tolerability, and Pharmacokinetics of CU-40101 Liniment in Single and Multiple Doses in Adult Male Androgenic Alopecia Subjects

AGA

China
Cutia Therapeutics（Wuxi）Co.,Ltd

Completed

A Phase 3 Clinical Study Patients With Androgenetic Alopecia (AGA)

AGA

China
Cutia Therapeutics（Wuxi）Co.,Ltd

Recruiting

A Phase 2 Clinical Study of CU-20401

Efficacy and Safety

China
Pulnovo Medical (Wuxi) Co., Ltd.

Not yet recruiting

Study for Evaluation of Safety and Efficacy of PADN to Treat Combined Post- and Pre- Capillary Pulmonary Hypertension Associated With Chronic Heart Failure

Heart Failure | Pulmonary Hypertension
D3 Bio (Wuxi) Co., Ltd

Recruiting

A Study of D3L-001 as Monotherapy in Subjects With HER2-Positive Advanced Solid Tumors

HER-2 Positive Advanced Solid Tumors

United States, China
Innovent Biologics (Suzhou) Co. Ltd.
WuXi CDS Clinical Research (Shanghai) Co.Ltd.

Completed

Evaluate the Efficacy and Safety of IBI305 in Patients With Advanced or Recurrent Non-squamous NSCLC

NSCLC

China
Forward Pharmaceuticals Co., Ltd.
WuXi Clinical

Recruiting

A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer (FWD1509)

Carcinoma, Non-Small-Cell Lung

United States
Hualan Biological Bacterin Co. Ltd.

Completed

Preliminary Study on Safety and Immunogenicity of Influenza A (H7N9) Vaccine in the Population

Influenza A
Hualan Biological Bacterin Co. Ltd.

Completed

Evaluate the Safety and Efficacy of Quadrivalent Influenza in Real-world Situations.

GCP

China
Changchun Zhuoyi Biological Co., Ltd

Enrolling by invitation

Prevention of Rabies With Four Doses of Rabies Vaccine

Rabies Human | Antibody

China
Hualan Biological Bacterin Co. Ltd.

Completed

Exploration on the Quadrivalent Influenza Vaccine Immunization Schedule for Children Aged 3-8 Years

GCP

China
Changchun Zhuoyi Biological Co., Ltd

Completed

Observation on the Immune Persistence of People Aged 10-60 Years Old Immunized With Five Doses of Rabies Vaccine

Rabies | Antibody

China
Changchun Zhuoyi Biological Co., Ltd

Completed

Vaccine Prevention of Rabies Adopts 4-shot Immunization Method

Rabies Human | Antibody Titer

China
Synermore Biologics Co., Ltd.

Completed

Comparison of the Safety and PK of SYN060 to Humira® in Healthy Adult Subjects

Arthritis, Rheumatoid

Australia
Synermore Biologics Co., Ltd.

Completed

Safety, Immunogenicity and Pharmacokinetics of SYN004 in Patients With Solid Tumors (SYN004_Ph_1)

Colon Cancer, Breast Cancer, Cancer of the Head and Neck

United States
Beijing Sanwater Biological Technology Co., Ltd.

Unknown

Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia

Acute Lymphoblastic Leukemia

China
Shanghai Qisheng Biological Preparation Co., Ltd.

Unknown

Medical Chitosan or Sodium Hyaluronate for Knee Osteoarthritis (CHOOSE)

Osteoarthritis, Knee

China
Ningbo Rongan Biological Pharmaceutical Co., Ltd.

Not yet recruiting

Clinical Trial of Freeze-dried Human Rabies Vaccine (Without Serum Vero Cells)

Rabies

China
Wuxi People's Hospital
Imbioray (Hangzhou) Biomedicine Co., Ltd.

Recruiting

Study of Anti-CD33/CLL1 CAR-NK in Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Changhai Hospital
Wuxi Hisky Medical Technology Co Ltd

Not yet recruiting

Confocal Laser Microendoscopy (CellTouch) for the Diagnosis of Early Gastric Cancer: A Multicenter Clinical Study

Early Gastric Cancer

China
Wuxi People's Hospital
Imbioray (Hangzhou) Biomedicine Co., Ltd.

Recruiting

Study of Anti-5T4 CAR-NK Cell Therapy in Advanced Solid Tumors

Advanced Solid Tumors

China
Shanghai Zerun Biotechnology Co.,Ltd
Yuxi Zerun Biotechnology Co., Ltd.

Completed

Lot Consistency Clinical Trial of Bivalent HPV Vaccine in 9 to 30 Years Old Healthy Females

HPV Infection

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors

Locally Advanced Solid Tumor

Australia
Tianjin ConjuStar Biologics Co., Ltd.

Recruiting

Study SC-101 in Subjects With Advanced Malignancies

Advanced Solid Tumor

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A First-in-human, Single-ascending-dose Study of IBI3002 in Healthy Participants and Mild to Moderate Asthmatics

Asthma | Healthy Participants

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI112 in Chinese Patients With Psoriasis Who Were Previously Treated With Biologics

Psoriasis

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors

Solid Tumor

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)

Non-squamous Non-small-cell Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A First-in-human Study of IBI354 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

Locally Advanced Unresectable or Metastatic Solid Tumors

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation

Advanced Non-Small Cell Lung Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer

Colorectal Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Phase 1, Open-label, Multicenter, Dose Escalation Study of IBI363 (PD1-IL2m) in Subjects With Advanced Solid Malignancies or Lymphomas

Solid Malignancies or Lymphomas

Australia
Innovent Biologics (Suzhou) Co. Ltd.

Not yet recruiting

A Phase Ib Study of Primary Efficacy and Safety of IBI321 Monotherapy or Combination Therapy in Patients With Advanced Solid Tumors

Advanced Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies

Advanced Solid Tumors

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study of IBI306 in Participants With Hypercholesterolemia

Hypercholesterolemia

China
Innovent Biologics (Suzhou) Co. Ltd.

Recruiting

A Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors

Advanced Malignancies

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Study of IBI362 in Chinese Patients With Type 2 Diabetes

Type 2 Diabetes

China
Innovent Biologics (Suzhou) Co. Ltd.

Terminated

A Safety, Tolerability, and Efficacy Study of IBI314 in Ambulatory Patients With COVID-19

COVID-19

United States
Innovent Biologics (Suzhou) Co. Ltd.

Completed

A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy

Advanced Cervical Cancer

China
Innovent Biologics (Suzhou) Co. Ltd.

Active, not recruiting

A Study of Longer Interval of IVT IBI302 in Subjects With nAMD

Neovascular Age-related Macular Degeneration

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects

Overweight or Obesity

China
Innovent Biologics (Suzhou) Co. Ltd.

Completed

Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure

Non-Squamous Non-Small Cell Lung Cancer

China

3

Subscribe